Synapse

← JHEP Reports

Papers in JHEP Reports

Page 3 · newest first

  1. Epithelial MLCK deficiency alleviates alcohol-associated liver disease via dendritic–Th17 cell axisJHEP Reports · 2026
  2. Recapitulation of Bile Acid Metabolism in Hepatobiliary Organoids Derived from hiPSCJHEP Reports · 2026
  3. Development and Psychometric Evaluation of the Liver Disease Stigma Scale (LDSS)JHEP Reports · 2026
  4. Elevated liver fat content is independently associated with insulin resistance in people with type 1 diabetesJHEP Reports · 2026
  5. Development of a CRISPR-Cas13-based antiviral strategy against hepatitis E virusJHEP Reports · 2026
  6. Global Structural Determinants of MASLD: Development-Stratified Pathways Linking Food Systems, Metabolic Risk, and Liver OutcomesJHEP Reports · 2026
  7. A novel pharmacological inhibitor of MAP4K4 activity attenuates metabolic dysfunction-associated steatohepatitisJHEP Reports · 2026
  8. IDH1 R132 mutations or HER2-positivity and benefit from platinum-based therapy for biliary tract cancersJHEP Reports · 2026
  9. Targeting a tolerogenic HLA-G genotype to tackle immune evasion and adaptive resistance in HBV-driven HCCJHEP Reports · 2026
  10. Spatial proteomics and cell-cell cross-talk analysis reveal PD-L1 and IL-6 interaction in human primary sclerosing cholangitisJHEP Reports · 2026
  11. Comparison of patients with HBV-related HCC with and without MASLD after liver transplantationJHEP Reports · 2026
  12. ANXA1-FPR1 signaling in myeloid cells drives MASH by elevating S100A4/A11JHEP Reports · 2026
  13. Robust HLA-B-restricted CD8+ T-cell responses in chronic HBV infectionJHEP Reports · 2026
  14. Molecular evolution of mosaic chromosome 18 copy-number alterations from gametes to hepatoblastomaJHEP Reports · 2026
  15. Haemodynamic alterations associated with hepatic vascular malformations in hereditary haemorrhagic telangiectasia: a cohort studyJHEP Reports · 2026
  16. Perioperative immunotherapy to reduce recurrence in resectable hepatocellular carcinoma - lessons learned from the CARES-009 trialJHEP Reports · 2026
  17. Treatment of liver failure utilizing multi-cell lineage liver microtissueJHEP Reports · 2026
  18. Severe hepatitis flares after antiviral withdrawal in chronic hepatitis B with lymphoma: Impact of rituximabJHEP Reports · 2026
  19. Persistent loss of intrahepatic IFN-γ in HBV is linked to selective impairment of liver-resident CXCR6+NK cells despite long-term NUC therapyJHEP Reports · 2026
  20. Targeting RuvBL1 disrupts mitochondrial metabolism and structure in hepatocellular carcinomaJHEP Reports · 2026
  21. Fatigue, depression, and impaired health-related quality of life in patients with vascular liver diseases: A multicentric European studyJHEP Reports · 2026
  22. Single-cell analysis reveals a LAMB3-dependent immunosuppressive environment in gallbladder neck/cystic duct carcinomaJHEP Reports · 2026
  23. AI-guided automated identification of patients at high risk for hepatocellular carcinoma in large US and global datasetsJHEP Reports · 2026
  24. Paediatric autoimmune liver disease in Europe, the prospective ERN R-LIVER registryJHEP Reports · 2026
  25. TCOF1 in Extracellular Vesicles predicts survival in HCC patients treated with High-Dose Conformal RadiotherapyJHEP Reports · 2026
  26. Role of the stromal and immune microenvironment in intrahepatic cholangiocarcinomaJHEP Reports · 2026
  27. Impact of Hepatocellular Carcinoma on the risk of liver decompensation: a comparative analysis of patients with and without HCCJHEP Reports · 2026
  28. Alcohol-Related Liver Disease Disrupts Bile Acid Homeostasis and Gut Microbial Bile Acid MetabolismJHEP Reports · 2026
  29. Zinc finger protein 544 promotes hepatocellular carcinoma by generating an immunosuppressive tumor microenvironmentJHEP Reports · 2026
  30. IMAT-HCC model: Liver Stiffness–Enhanced Integrated Risk Stratification for HCC Recurrence After ResectionJHEP Reports · 2026
  31. Scientific, regulatory, and practical considerations for bringing hepatocellular carcinoma biomarkers into clinical practiceJHEP Reports · 2026
  32. Alcohol-driven phenotypic transition in MASLD and risk of liver-related eventsJHEP Reports · 2026
  33. The future of hepatology: Preventing liver disease together with the public, scientists and artificial intelligenceJHEP Reports · 2026
  34. Intrahepatic T cell analysis reveals Th17 and MAIT17 enrichment in primary sclerosing cholangitisJHEP Reports · 2026
  35. Are FIB-4 and liver stiffness measurement interchangeable for HCC risk stratification in MASLD?JHEP Reports · 2026
  36. Response-guided bulevirtide ± pegylated interferon alfa-2a: long-term outcomes observed in the nationwide Austrian hepatitis D cohort studyJHEP Reports · 2026
  37. AI-Guided Additive Scoring Model for Differential Diagnosis of Primary Liver CancerJHEP Reports · 2026
  38. Advanced: post-hoc analysis of the ABC-01, -02 and -03 clinical trials.JHEP Reports · 2026
  39. Net benefit of surveillance varies by hepatocellular carcinoma risk in patients with cirrhosisJHEP Reports · 2026
  40. Elevation of liver elasticity following radiofrequency ablation reflects neutrophil-mediated abscopal effect in liver cancerJHEP Reports · 2026
  41. Platelet hyperactivation drives oxidized mitochondrial DNA–induced neutrophil extracellular traps formation in biliary atresiaJHEP Reports · 2026
  42. Dental prophylactic Interventions are Associated with Lower Decompensation-related Hospitalizations over 2 years in CirrhosisJHEP Reports · 2026
  43. Atezolizumab–Bevacizumab in Very Elderly With Hepatocellular Carcinoma: Age Alone Is Not a Limiting Factor Except in ALBI Grade 3JHEP Reports · 2026
  44. Liver transplantation in unresectable intrahepatic cholangiocarcinoma following neoadjuvant chemotherapy and SIRTJHEP Reports · 2026
  45. Irreversible electroporation vs. stereotactic body radiotherapy for solitary hepatocellular carcinoma ≤5 cm: A multicenter retrospective studyJHEP Reports · 2026
  46. Cell-SELEX identifies a DNA aptamer for highly selective in vivo siRNA delivery in cholangiocarcinomaJHEP Reports · 2026
  47. PERSoN4: A Multiparametric Ultrasound Model to Improve CEUS LI-RADS for HCCJHEP Reports · 2026
  48. Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunctionJHEP Reports · 2026
  49. Evaluation of novel assays of non-ceruloplasmin copper to monitor chelation treatment in patients with Wilson diseaseJHEP Reports · 2026
  50. Wilson Disease is a single gene disorder - comprehensive analysis of patients with prior negative genetic testingJHEP Reports · 2026